Clinical trials: Pegfilgrastim
Rhabdomyosarcoma
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
This is a phase II study to determine safety and efficacy of combining liposomal irinotecan with vincristine alternating with VAC in intermediate-risk patients, liposomal irinotecan with temozolomide and vincristine alternating…
- Trial name
- NCT06023641
- Testing
- Vincristine, Dactinomycin, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- St. Jude Children's Research Hospital
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
This phase II trial is studying how well giving rituximab together with combination chemotherapy and bortezomib works in treating patients with untreated mantle cell lymphoma.
- Conditions
- Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma
- Trial name
- NCT00433537
- Testing
- bortezomib, rituximab, cyclophosphamide
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
Safety and Immunogenicity of MSB11455 in Healthy Participants
The primary purpose of this study is to compare the immunogenicity and safety of MSB11455 and Neulasta in healthy adult participants.
- Trial name
- NCT03251339
- Testing
- MSB11455, US-Neulasta
- Where
- 2 sites in New Zealand
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Stage III Breast Cancer AJCC V7
Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer
Molecular markers predicting response to dose dense chemotherapy with epirubicin and docetaxel in sequence for locally advanced breast cancer Protocol summary. Principal Investigator Hans P. Eikesdal, Professor, Dept.
- Trial name
- DDP (NCT00496795)
- Testing
- epirubicin/docetaxel sequential
- Where
- Norway
- Volunteers
- 100 people
- Sponsor
- University of Bergen
Sarcoma, Soft Tissue
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma
The purpose of this study is to explore how a sarcoma is affected by and the side effects of a newer combination of chemotherapy drugs(gemcitabine and docetaxel)as compared to a standard combination of chemotherapy drugs…
- Trial name
- NCT00189137
- Testing
- ifosfamide and doxorubicin vs gemcitabine and docetaxel
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chemotherapy-induced Neutropenia
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
The primary purpose of this study is to compare the percentage of patients with Duration of Severe Neutropenia (DSN) =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus…
- Trial name
- NCT03294577
- Testing
- Pegfilgrastim, Plinabulin, Docetaxel, doxorubicin, and cyclophosphamide (TAC)
- Where
- 20 sites in China, Ukraine
- Volunteers
- 221 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Breast Cancer
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
This trial will compare 6 versus 12 months of trastuzumab in combination with dose dense docetaxel following FE75C as adjuvant chemotherapy in women with axillary lymph node positive breast cancer overexpressing HER2
- Trial name
- NCT00615602
- Testing
- Docetaxel, Trastuzumab, Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 489 people
- Sponsor
- Hellenic Oncology Research Group
Non-small Cell Lung Cancer
Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer
Dose-dense chemotherapy is a chemotherapy treatment plan in which drugs are given with less time between treatments than in standard chemotherapy.
- Trial name
- NCT02157116
- Testing
- cisplatin, Docetaxel, Pegfilgrastim
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Duke University
Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00974792
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cancer Research UK
Lymphoma, Myeloma
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma
The purpose of this study is to evaluate the efficacy and tolerance of a single administration of Pegfilgrastim in patients with lymphoma or myeloma receiving high-dose chemotherapy and autologous peripheral stem cell support…
- Trial name
- PALM (NCT00794261)
- Testing
- Injection of Pegfilgrastim, Injection of Filgrastim
- Where
- 11 sites in France
- Volunteers
- 150 people
- Sponsor
- Centre Leon Berard
Breast Cancer
TAC Versus TC for Adjuvant Breast Cancer
The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.
- Trial name
- NCT00493870
- Testing
- Docetaxel, Doxorubicin, Cyclophosphamide
- Where
- 95 sites in United States
- Volunteers
- 1,961 people
- Sponsor
- US Oncology Research
Healthy
Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim
The goal of this prospective, observational study is to compare the quality and quantity of the cellular content of platelet-rich plasma harvested after administering one of two cell-stimulating proteins, filgrastim and…
- Trial name
- M-PRP (NCT05573386)
- Testing
- Filgrastim, Pegfilgrastim
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Andrews Research & Education Foundation
Healthy Volunteers
A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers
This study compares the immune response to the proposed biosimilar PF-06881894 and the US-approved Neulasta reference product. Subjects will receive 2 subcutaneous injections (6 milligrams [mg]) either 1 of the 2 study drugs.
- Trial name
- NCT03273842
- Testing
- PF-06881894, US-approved Neulasta
- Where
- 4 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Pfizer
Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
This pilot study is evaluating how well pembrolizumab and combination chemotherapy before surgery work for the treatment of specific types of muscle-invasive bladder cancer that have unusual appearance (variants).
- Conditions
- Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
- Trial name
- NCT04383743
- Testing
- Cisplatin, Doxorubicin, Methotrexate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Washington
Breast Cancer
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070564
- Testing
- pegfilgrastim, AC regimen, cyclophosphamide
- Where
- 542 sites in United States, Canada and 1 more
- Volunteers
- 3,294 people
- Sponsor
- SWOG Cancer Research Network
Patient Preference, Febrile Neutropenia, Drug-Induced
Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim
Febrile neutropenia (NF) is a common serious complication of cancer chemotherapy. Outpatient management of chemotherapy treatments is made essential by the volume of patients treated, respect for their quality of life and the…
- Conditions
- Patient Preference, Febrile Neutropenia, Drug-Induced, Patient Satisfaction
- Trial name
- PELGRAZ (NCT05910164)
- Testing
- PELGRAZ prefilled syringe or PELGRAZ prefilled pen
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Institut Rafael
Sarcoma
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
This is a Phase Ib/II experimental, open-label, dose escalation, active treatment study designed to determine the safety, tolerability, and recommended dose of the combination.
- Trial name
- GemTax (NCT01879085)
- Testing
- Docetaxel, Gemcitabine, Vorinostat
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Melissa Burgess, MD
Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients with relapsed or refractory classic Hodgkin lymphoma (cHL) with…
- Conditions
- Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma
- Trial name
- NCT07021989
- Testing
- Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Michael Spinner, MD
Germ Cell Tumor
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.
- Trial name
- P3BEP (NCT02582697)
- Testing
- Bleomycin (active name: Bleomycin Sulfate), Etoposide, Cisplatin
- Where
- 56 sites in United States, Australia and 2 more
- Volunteers
- 500 people
- Sponsor
- University of Sydney
Malignant Peripheral Nerve Sheath Tumors (MPNST)
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation.
- Trial name
- NCT04872543
- Testing
- ASTX727
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center